High Infiltration of CD203c⁺ Mast Cells Reflects Immunosuppression and Hinders Prognostic Benefit in Stage II-III Colorectal Cancer

References

• Galli SJ, Borregaard N, Wynn TA. Phenotypic and functional plasticity of cells of innate immunity: macrophages, mast cells and neutrophils. Nat Immunol. 2011;12:1035–1044. doi:10.1038/ni.2109
   PubMed Web of Science ®Google Scholar
• Galli SJ, Tsai M, Piliponsky AM. The development of allergic inflammation. Nature. 2008;454(7203):445–454. doi:10.1038/nature07204
   PubMed Web of Science ®Google Scholar
• Amin K. The role of mast cells in allergic inflammation. Respir Med. 2012;106(1):9–14. doi:10.1016/j.rmed.2011.09.007
   PubMed Web of Science ®Google Scholar
• Khazaie K, Blatner NR, Khan MW, et al. The significant role of mast cells in cancer. Cancer Metastasis Rev. 2011;30(1):45–60. doi:10.1007/s10555-011-9286-z
   PubMed Web of Science ®Google Scholar
• Dudeck A, Dudeck J, Scholten J, et al. Mast cells are key promoters of contact allergy that mediate the adjutant effects of haptens. Immunity. 2011;34:973–984. doi:10.1016/j.immuni.2011.03.028
   PubMed Web of Science ®Google Scholar
• de Vries VC, Pino-Lagos K, Nowak EC, et al. Mast cells condition dendritic cells to mediate allograft tolerance. Immunity. 2011;35:550–561. doi:10.1016/j.immuni.2011.09.012
   Web of Science ®Google Scholar
• Tan SY, Fan Y, Luo HS, et al. Prognostic significance of mast cell infiltrations of immunosurveillance in colorectal cancer. World J Gastroenterol. 2005;11:1210–1214. doi:10.3748/wjg.v11.i8.1210
   PubMed Web of Science ®Google Scholar
• Nielsen HJ, Hansen U, Christensen IJ, et al. Independent prognostic value of eosinophil and mast cell infiltration in colorectal cancer tissue. J Pathol. 1999;189:487–495. doi:10.1002/(SICI)1096-9896(199912)189:4<487::
   PubMed Web of Science ®Google Scholar
• Malfettone A, Silvestris N, Saponaro C, et al. High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression. J Cell Mol Med. 2013;17:1025–1037. doi:10.1111/jcmm.12073
   PubMed Web of Science ®Google Scholar
• Mehdawi L, Osman J, Topi G, et al. High tumor mast cell density is associated with longer survival of colon cancer patients. Acta Oncol. 2016;55:1434–1442. doi:10.1080/0284186X.2016.1198493
   PubMed Web of Science ®Google Scholar
• Acikalin MF, Oner U, Topçu I, et al. Tumour angiogenesis and mast cell density in the prognostic assessment of colorectal carcinomas. Dig Liver Dis. 2005;37:162–169. doi:10.1016/j.dld.2004.09.028
   PubMedGoogle Scholar
• Gulubova M, Vlaykova T. Prognostic significance of mast cell number and microvascular density for the survival of patients with primary colorectal cancer. J Gastroenterol Hepatol. 2009;24:1265–1275. doi:10.1111/j.1440-1746.2007.05009.x
   PubMed Web of Science ®Google Scholar
• Elezoglu B, Tolunay S. The relationship between the stromal mast cell number, micro-vessel density, c-erbB-2 staining and survival and prognostic factors in colorectal carcinoma. Turk Patoloji Derg. 2012;28(2):110–118. doi:10.5146/tjpath.2012.01109
   Google Scholar
• Wu X, Zou Y, He X, et al. mast cells in colorectal cancer as a poor prognostic factor. Int J Surg Pathol. 2013;21(2):111–120. doi:10.1177/1066896912448836
   Web of Science ®Google Scholar
• Ammendola M, Sacco R, Sammarco G, et al. Correlation between serum tryptase, mast cells positive to tryptase and microvascular density in colorectal cancer patients: possible biological-clinical significance. PLoS One. 2014;9(6):e9851. doi:10.1371/journal.pone.0099512
   Web of Science ®Google Scholar
• Suzuki S, Ichikawa Y, Nakagawa K, et al. High infiltration of mast cells positive to tryptase predicts worse outcome following resection of colorectal liver metastases. BMC Cancer. 2015;15:840. doi:10.1186/s12885-015-1863-z
   Web of Science ®Google Scholar
• Chen Y, Yuan R, Wu X, et al. A novel immune marker model predicts oncological outcomes of patients with colorectal cancer. Ann Surg Oncol. 2016;23(3):826–832. doi:10.1245/s10434-015-4889-1
   Web of Science ®Google Scholar
• Mao Y, Feng Q, Zheng P, et al. Low tumor infiltrating mast cell density confers prognostic benefit and reflects immunoactivation in colorectal cancer. Int J Cancer. 2016;143(9):2271–2280. doi:10.1002/ijc.31613
   Web of Science ®Google Scholar
• Yano Y, Hayashi Y, Sano K, et al. Expression and localization of ectonucleotide pyrophosphatase/phosphodiesterase I-3(E-NPP3/CD203c/PD-Ibeta/B10/gp130RB13-6) in human colon carcinoma. Int J Mol Med. 2003;12(5):763–766.
   Web of Science ®Google Scholar
• Doñate F, Raitano A, Morrison K, et al. AGS16F is a novel antibody drug conjugate directed against ENPP3 for the treatment of renal cell carcinoma. Clin Cancer Res. 2016;22(8):1989–1999. doi:10.1158/1078-0432.CCR-15-1542
   Web of Science ®Google Scholar
• Iwamoto T, Yuta A, Tabata T, et al. Evaluation of basophil CD203c as a predictor of carboplatin-related hypersensitivity reaction in patients with gynecologic cancer. Biol Pharm Bull. 2012;35(9):1487–1495. doi:10.1248/bpb.b12-00150
   Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Liu CL, et al. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259. doi:10.1007/978-1-4939-7493-1_12
   PubMedGoogle Scholar
• Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci. 2005;102(43):15545–15550. doi:10.1073/pnas.0506580102
   PubMed Web of Science ®Google Scholar
• Ogłuszka M, Orzechowska M, Jędroszka D, et al. Evaluate cutpoints: adaptable continuous data distribution system for determining survival in Kaplan-Meier estimator. Comput Methods Programs Biomed. 2019;177:133–139. doi:10.1016/j.cmpb.2019.05.023
   PubMed Web of Science ®Google Scholar
• Hu X, Li C, Chen J, Qin G. Confidence intervals for the Youden index and its optimal cut-off point in the presence of covariates. J Biopharm Stat. 2021;31(3):251–272. doi:10.1080/10543406.2020.1832107
   PubMed Web of Science ®Google Scholar
• Martínez-Camblor P, Pardo-Fernández JC. The Youden Index in the Generalized Receiver Operating Characteristic Curve Context. Int J Bio Stat. 2019;15(1). doi:10.1515/ijb-2018-0060
   Google Scholar
• Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors [J]. Stat Med. 1996;15:361–387. doi:10.1002/(SICI)1097-0258(19960229)15:4<361::
   PubMed Web of Science ®Google Scholar
• Iasonos A, Schrag D, Raj GV, et al. How to build and interpret a nomogram for cancer prognosis [J]. J Clin Oncol. 2008;26:1364–1370. doi:10.1200/JCO.2007.12.9791
   PubMed Web of Science ®Google Scholar
• Iveson TJ, Sobrero AF, Yoshino T, et al. Duration of adjutant doublet chemotherapy (3 or 6 months) in patients with high-risk stage II colorectal cancer. J Clin Oncol. 2021;39(6):631–641. doi:10.1200/JCO.20.01330
   Web of Science ®Google Scholar
• Yamazaki K, Yamanaka T, Shiozawa M, et al. Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized Phase III ACHIEVE-2 trial. Ann Oncol. 2021;32(1):77–84. doi:10.1016/j.annonc.2020.10.480
   PubMed Web of Science ®Google Scholar
• Yothers G, O’Connell MJ, Allegra CJ, et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol. 2011;29(28):3768–3774. doi:10.1200/JCO.2011.36.4539
   PubMed Web of Science ®Google Scholar
• Haller DG, Tabernero J, Maroun J, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011;29(11):1465–1467. doi:10.1200/JCO.2010.33.6297
   PubMed Web of Science ®Google Scholar
• André T, Meyerhardt J, Iveson T, et al. Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, Phase 3 trials. Lancet Oncol. 2020;21(12):1620–1629. doi:10.1016/S1470-2045(20)30527-1
   PubMed Web of Science ®Google Scholar
• O’Connor ES, Greenblatt DY, LoConte NK, et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol. 2011;29(25):3381–3388. doi:10.1200/JCO.2010.34.3426
   PubMed Web of Science ®Google Scholar
• Lv Y, Zhao Y, Wang X, et al. Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway. J Immunother Cancer. 2019;7(1):54. doi:10.1186/s40425-019-0530-3
   PubMed Web of Science ®Google Scholar
• Somasundaram R, Connelly T, Choi R, et al. Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy. Nat Commun. 2021;12(1):346. doi:10.1038/s41467-020-20600-7
   PubMed Web of Science ®Google Scholar
• Grothey A, Sobrero AF, Shields AF, et al. Duration of adjuvant chemotherapy for stage III colon cancer. N Engl J Med. 2018;378(13):1177–1188. doi:10.1056/NEJMoa1713709
   PubMed Web of Science ®Google Scholar